NEW YORK (GenomeWeb News) – Pacific Biosciences reported after the close of the market Tuesday that its third quarter 2013 revenues climbed 164 percent year over year and grew 23 percent sequentially.

The Menlo Park, Calif.-based single-molecule sequencing technologies firm reported Q3 revenues of $7.4 million, compared to just $2.8 million in Q3 2012 and up from $6 million in Q2 2013. It beat the consensus Wall Street estimate of $7.1 million in revenues for the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.